Literature DB >> 21263244

High lymphatic vessel density and lymphatic invasion underlie the adverse prognostic effect of radial growth phase regression in melanoma.

Sook Jung Yun1, Phyllis A Gimotty, Wei-Ting Hwang, Peter Dawson, Patricia Van Belle, David E Elder, Rosalie Elenitsas, Lynn Schuchter, Paul J Zhang, DuPont Guerry, Xiaowei Xu.   

Abstract

Regression in the radial growth phase (RGP) of primary cutaneous melanomas is common and has been shown to be an adverse prognostic factor. However, the underlying mechanism is unclear. We performed dual immunohistochemical staining of podoplanin and S-100 on paraffin tissues from 321 patients with vertical growth phase primary melanomas, who had 10 years or more of follow-up. Lymphatic vessel density (LD) and lymphatic invasion (LI) were quantified and documented. The time to first metastasis and melanoma-specific death (MSD) from the date of definite treatment were analyzed using univariate and multivariate Cox models. Among the 116 vertical growth phase melanomas that had regression in the adjacent RGP, 75 (23%) were classified as complete and 41 (13%) were classified as partial. LD was significantly higher (P<0.001) in the 75 lesions with complete regression (mean±SD, 23.7±12.3/mm²) compared with the 41 lesions with partial regression (15.5±7.1/mm²) and was lower in 155 areas of the adjacent normal dermis (7.3±3.5/mm²) and 69 areas of the distant normal dermis (5.5±2.6/mm²). Patients whose lesions had areas of complete regression with LI and either high or low LD or had no LI with high LD, had shorter time to first metastasis (hazard ratio=2.5, 3.8, and 2.5, respectively) and increased risk of melanoma-specific death (hazard ratio=3.1, 1.3 and 3.0, respectively) than those with no LI, and low LD or those without areas of complete regression. These data indicate that complete RGP regression is associated with significantly increased LD. In addition, the adverse prognostic effect of RGP regression is at least partially mediated through lymphangiogenesis and LI in this area.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21263244      PMCID: PMC3062088          DOI: 10.1097/PAS.0b013e3182036ccd

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  27 in total

1.  Tumour regression predicts higher risk of sentinel node involvement in thin cutaneous melanomas.

Authors:  J Oláh; R Gyulai; I Korom; E Varga; A Dobozy
Journal:  Br J Dermatol       Date:  2003-09       Impact factor: 9.302

2.  A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors.

Authors:  Harriette J Kahn; Alexander Marks
Journal:  Lab Invest       Date:  2002-09       Impact factor: 5.662

3.  Lymphatic vessel density is significantly increased in melanoma.

Authors:  T A Giorgadze; P J Zhang; T Pasha; P S Coogan; G Acs; D E Elder; X Xu
Journal:  J Cutan Pathol       Date:  2004-11       Impact factor: 1.587

4.  Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth.

Authors:  T Karpanen; M Egeblad; M J Karkkainen; H Kubo; S Ylä-Herttuala; M Jäättelä; K Alitalo
Journal:  Cancer Res       Date:  2001-03-01       Impact factor: 12.701

5.  Independent prognostic impact of lymphatic vessel density and presence of low-grade lymphangiogenesis in cutaneous melanoma.

Authors:  Oddbjørn Straume; David G Jackson; Lars A Akslen
Journal:  Clin Cancer Res       Date:  2003-01       Impact factor: 12.531

6.  Partial regression of primary cutaneous melanoma: is there an association with sub-clinical sentinel lymph node metastasis?

Authors:  Dan Fontaine; Winston Parkhill; Wenda Greer; Noreen Walsh
Journal:  Am J Dermatopathol       Date:  2003-10       Impact factor: 1.533

7.  Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival.

Authors:  Soheil S Dadras; Thomas Paul; Jennifer Bertoncini; Lawrence F Brown; Alona Muzikansky; David G Jackson; Ulf Ellwanger; Claus Garbe; Martin C Mihm; Michael Detmar
Journal:  Am J Pathol       Date:  2003-06       Impact factor: 4.307

8.  Selective immunohistochemical staining shows significant prognostic influence of lymphatic and blood vessels in patients with malignant melanoma.

Authors:  J Valencak; E Heere-Ress; T Kopp; S F Schoppmann; H Kittler; H Pehamberger
Journal:  Eur J Cancer       Date:  2004-02       Impact factor: 9.162

9.  Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis.

Authors:  Sebastian F Schoppmann; Peter Birner; Johannes Stöckl; Romana Kalt; Robert Ullrich; Carola Caucig; Ernst Kriehuber; Katalin Nagy; Kari Alitalo; Dontscho Kerjaschki
Journal:  Am J Pathol       Date:  2002-09       Impact factor: 4.307

10.  Lymphatic density and metastatic spread in human malignant melanoma.

Authors:  J D Shields; M Borsetti; H Rigby; S J Harper; P S Mortimer; J R Levick; A Orlando; D O Bates
Journal:  Br J Cancer       Date:  2004-02-09       Impact factor: 7.640

View more
  13 in total

1.  Stromal inflammatory cells are associated with poorer prognosis in primary cutaneous melanoma.

Authors:  Sook Jung Yun; Shujing Liu; Meghan Buckley; Tao Wang; Suna Jin; Giorgos Karakousis; Madalyn G Peters; David E Elder; Phyllis A Gimotty; Xiaowei Xu
Journal:  Hum Pathol       Date:  2019-04-06       Impact factor: 3.466

2.  Regression in primary cutaneous melanoma: etiopathogenesis and clinical significance.

Authors:  Phyu P Aung; Priyadharsini Nagarajan; Victor G Prieto
Journal:  Lab Invest       Date:  2017-02-27       Impact factor: 5.662

3.  Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma.

Authors:  David L Bajor; Xiaowei Xu; Drew A Torigian; Rosemarie Mick; Laura R Garcia; Lee P Richman; Cindy Desmarais; Katherine L Nathanson; Lynn M Schuchter; Michael Kalos; Robert H Vonderheide
Journal:  Cancer Immunol Res       Date:  2014-09-24       Impact factor: 11.151

4.  Lymphatic invasion as a prognostic biomarker in primary cutaneous melanoma.

Authors:  Xiaowei Xu; Phyllis A Gimotty; Dupont Guerry; Giorgos Karakousis; David E Elder
Journal:  Methods Mol Biol       Date:  2014

Review 5.  Construction and analysis of multiparameter prognostic models for melanoma outcome.

Authors:  Bonnie E Gould Rothberg; David L Rimm
Journal:  Methods Mol Biol       Date:  2014

Review 6.  Tissue prognostic biomarkers in primary cutaneous melanoma.

Authors:  Mario Mandalà; Daniela Massi
Journal:  Virchows Arch       Date:  2014-02-01       Impact factor: 4.064

7.  Lymphatic invasion and angiotropism in primary cutaneous melanoma.

Authors:  Andrea P Moy; Lyn M Duncan; Stefan Kraft
Journal:  Lab Invest       Date:  2016-12-19       Impact factor: 5.662

8.  Lymphatic invasion is independently prognostic of metastasis in primary cutaneous melanoma.

Authors:  Xiaowei Xu; Lianjun Chen; DuPont Guerry; Peter R Dawson; Wei-ting Hwang; Patricia VanBelle; David E Elder; Paul J Zhang; Michael E Ming; Lynn Schuchter; Phyllis A Gimotty
Journal:  Clin Cancer Res       Date:  2011-11-17       Impact factor: 12.531

9.  Lymphatic invasion predicts aggressive behavior in melanocytic tumors of uncertain malignant potential (MELTUMP).

Authors:  Ronnie M Abraham; Giorgos Karakousis; Geza Acs; Amy F Ziober; Lorenzo Cerroni; Martin C Mihm; David E Elder; Xiaowei Xu
Journal:  Am J Surg Pathol       Date:  2013-05       Impact factor: 6.394

10.  Mouse lymphatic endothelial cell targeted probes: anti-LYVE-1 antibody-based magnetic nanoparticles.

Authors:  Qiu Guo; Yi Liu; Ke Xu; Ke Ren; WenGe Sun
Journal:  Int J Nanomedicine       Date:  2013-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.